Moventig®
Moventig® is indicated for the treatment of opioid induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. It is the first oral once daily peripherally acting mu-opioid receptor antagonist (PAMORA) that selectively blocks mu-opioid receptors in the bowel, providing patients relief from opioid induced constipation (OIC) without impacting their pain control.
This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information: